Pevion Biotech agreed to manufacture Biolife Science's HER-Vaxx cancer vaccine for use in midstage trials for the treatment of gastric cancer. Pevion will be eligible for royalties on eventual sales of HER-Vaxx, which was developed using Pevion's vaccine technology and Biolife's peptides. Biolife plans to submit the vaccine for FDA approval in the third quarter.